Fundraising FoxKairos Venture Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Linnaeus Therapeuticslinnaeustx.cominFeb 2026SEC filingmedium confidence
Clinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.
BiotechHaddonfield, US
Patrick T. Mooney(Executive Officer)in
BoardTodd Thomson(Director)inMichael D. Poisel(Director)Chris Arendt(Director)
Board seatJames Demetriades· per SEC Form D · $10M raise · filed Apr 2026
Co-investorsKairos Venture Investments, LlcIA Global
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.